Share
    NEW SEARCH RETURN TO SEARCH RESULTS
Number: 201108120 Principal Investigator: Vij, Ravi
Title: Phase I/II Study of combination of Aurora Kinase Inhibitor MLN8237 and Bortezomib in Relapsed or Refractory Multiple Myeloma (MMRC/MC088A)
Phase: I/II Disease Site: Multiple Myeloma
Participating Site(s):
 
Main Campus
Map and Directions
 
Contact: 800-600-3606 or info@ccadmin.wustl.edu
Description:
This study is being done to find out what good and bad effects the drug MLN8237 and bortezomib have on patients and multiple myeloma.

There will be up to 63 patients treated in this research study. Approximately 10 patients will take part in this study at Washington University.
 
More Information:
ClinicalTrials.gov Link
Internal Protocol Documents (requires Siteman administrative database password)